Evidence map›Paper›PMID 27088073›Full record

ArticleCurrent pharmacology reports2016

Oxidative Stress: A Promising Target for Chemoprevention.

Am Sashi Papu John, Murali K Ankem, Chendil Damodaran

Open access · bronzeAbstract read
In one paragraph

Article in Current pharmacology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. The intricacies of NRF2 regulation in cancer.Seminars in cancer biology · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Am Sashi Papu JohnDepartment of Urology, University of Louisville, KY 40202.
Murali K AnkemDepartment of Urology, University of Louisville, KY 40202.
Chendil DamodaranDepartment of Urology, University of Louisville, KY 40202.
University of Louisville · US

Funding

Chemoprevention of metastatic colorectal cancerR01CA185972 · NCI · UNIVERSITY OF LOUISVILLE · PI DAMODARAN, CHENDIL · 2014 to 2018
$2.0M
Targeting AR and Akt for the Treatment of Prostate CancerR01CA138797 · NCI · UNIVERSITY OF LOUISVILLE · PI DAMODARAN, CHENDIL · 2010 to 2015
$1.5M
Dietary prevention of prostate cancerR01CA140605 · NCI · UNIVERSITY OF LOUISVILLE · PI DAMODARAN, CHENDIL · 2010 to 2015
$1.5M
NCI NIH HHS R01 CA138797NCI NIH HHS R01 CA140605NCI NIH HHS R01 CA185972
6 · The paper itself

Abstract

Cancer is a leading cause of death worldwide, and treating advanced stages of cancer remains clinically challenging. Epidemiological studies have shown that oxidants and free radicals induced DNA damage is one of the predominant causative factors for cancer pathogenesis. Hence, oxidants are attractive targets for chemoprevention as well as therapy. Dietary agents are known to exert an anti-oxidant property which is one of the most efficient preventive strategy in cancer progression. In this article, we highlight dietary agents can potentially target oxidative stress, in turn delaying, preventing, or treating cancer development. Some of these agents are currently in use in basic research, while some have been launched successfully into clinical trials.

Identifiers

PMID27088073
PMCPMC4827866
OpenAlexW2253027048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.